Navigation Links
USP Convention and Chinese Pharmacopoeia Commission sign Memorandum of Understanding
Date:3/6/2008

Rockville, Md., March 6, 2008 The U.S. Pharmacopeial Convention (USP) and the Chinese Pharmacopoeia Commission (ChP) this week signed a Memorandum of Understanding (MOU) with the purpose of working together to strengthen the quality of medicines and foods in the United States and China.

Roger L. Williams, M.D., USP executive vice president and CEO, and Wu Zhen, secretary-general of ChP and deputy commissioner of Chinas State Food and Drug Administration (SFDA), signed the MOU at USPs Headquarters in Rockville, Md. A Chinese delegation of representatives from the ChP and the SFDA joined Mr. Wu in visiting USP.

USP is pleased to partner with the Chinese Pharmacopoeia Commission on this Memorandum of Understanding, said Dr. Williams. This agreement represents our combined commitment to improving patient care and advancing the public health in the United States and China through rigorous quality standards for medicines. The agreement is a renewal of a prior agreement that had been in place for several years.

The Chinese Pharmacopoeia Commission looks forward to a long-term relationship with USP in which we exchange our scientific expertise and work together on a variety of activities that will benefit all consumers of medicine in our respective countries, added Mr. Wu.

Potential areas of collaboration identified in the MOU include:

  • Standards In order to strengthen documentary and physical standards which assure the quality of medicines, foods and other health care products USP and ChP will develop processes to update existing monograph standards and acquire new monographs.
  • Third-Party Certification (Verification) To advance the availability of good quality pharmaceutical ingredients used to produce medicines in China and the United States for export, USP and ChP will explore ways to develop approaches to allow review, testing and audits of manufacturers of ingredients imported into China and those manufacturing for export from China to the United States.
  • Translation To assure the availability and use of USP compendia among Chinese-speaking people, USP and ChP will explore ways to expedite the translation of USP compendia into Chinese. Conversely, USP and ChP will consider ways for USP to review the quality of the English translation of the Chinese Pharmacopoeia.
  • Working Relationships To facilitate knowledge exchange, USP and ChP will hold a joint scientific symposium biannually alternating between the United States and China; hold meetings between senior management of both groups at least once a year; and exchange scientific staff.

USP and ChP have maintained a strong working relationship since 1990, when USP staff first visited ChP. Since then, the organizations have co-sponsored two scientific meetings and signed an initial MOU in 2005, which laid the foundation for further cooperation.

USP sets federally recognized standards for the quality, purity and strength of prescription and over-the-counter medications sold in the United States, as well as widely recognized standards for dietary supplements and food ingredients. ChP holds legal responsibility in China for creating and revising national medicine standards, including traditional Chinese medicines (TCM). Some TCM products may be considered both drugs in the United States and dietary supplements.


'/>"/>

Contact: Sandra Kim
sek@usp.org
301-816-8241
US Pharmacopeia
Source:Eurekalert

Related biology news :

1. UC-Riverside partners with Chinese university to address Chinas environmental problems
2. Dartmouth researchers alarmed by levels of mercury and arsenic in Chinese freshwater ecosystem
3. 2008 Pew Fellowship in Marine Conservation awarded to Fan Meng; first Chinese fellow
4. e-Smart Technologies, Inc. Responds to Information Subpoenas From Securities & Exchange Commission
5. A study by the MUHC and McGill University opens a new door to understanding cancer
6. Understanding hypertension in African Americans proves elusive
7. Systems Biology poised to revolutionize the understanding of cell function and disease
8. Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer
9. Understanding, combating foodborne pathogens E. coli 0157 and salmonella
10. Researchers discover important tool in understanding differentiation in human embryonic stem cells
11. Atmospheric measuring device for understanding smog formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: